A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia [PDF]
, 2013 AIMS: The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD).
Farlow, Martin R. +4 more
core +2 more sources
Insights into (S)-rivastigmine inhibition of butyrylcholinesterase (BuChE): Molecular docking and saturation transfer difference NMR (STD-NMR) [PDF]
, 2016 Rivastigmine is a very important drug prescribed for the treatment of Alzheimer's disease (AD) symptoms. It is a dual inhibitor, in that it inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).
Bacalhau, P +3 more
core +1 more source
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia [PDF]
Journal of Movement Disorders, 2015 Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine ...
Yoon-Sang Oh +2 more
doaj +1 more source
Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. [PDF]
, 2015 OBJECTIVE: The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia.
Cambridge, Victoria +9 more
core +2 more sources
Antimuscarinic delirium in a pediatric patient reversed with transdermal rivastigmine: A case report
JEM ReportsBackground: Antidotal treatment of antimuscarinic delirium (AMD) standardly involves parenteral administration of physostigmine. However, due to cessation of physostigmine production, administration of oral or transdermal rivastigmine may serve as a ...
Natalie E. Ebeling-Koning +5 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale +5 more
wiley +1 more source
Effect of Rivastigmine on Mobility of Patients with Higher-Level Gait Disorder: A Pilot Exploratory Study [PDF]
, 2014 Background: Higher-level gait disorder (HLGD) in older adults is characterized by postural instability, stepping dysrhythmicity, recurrent falls and progressive immobility. Cognitive impairments are frequently associated with HLGD. Objectives: The aim of
Balash, Yacov +6 more
core +2 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
NICE 2011 recommendations on the management of Alzheimer’s disease by acetylcholinesterase inhibitors and memantine [PDF]
, 2011 The National Institute of Clinical Excellence (NICE) has lately overturned its decision to restrict the use of acetycholinesterase inhibitors and memantine in patients diagnosed with Alzheimer’s disease (AD).
Scerri, Charles
core
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]
, 2015 In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani +9 more
core +3 more sources